TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11532463

Group type: EXPERIMENTAL
Intervention: Continuous transdermal E(2) plus acetate nomegestrolo (group A1)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Transdermal E(2) continuously administered (group B1)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Short-term suspension of HRT (group A2)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Short-term suspension of HRT (group B2)
Number of subjects: 97

Group type: COMPARATOR
Intervention: No medication (group C)
Number of subjects: 97
Study: 9754191

Group type: EXPERIMENTAL
Intervention: Ketorolac 0.5% ophthalmic solution
Number of subjects: 120

Group type: COMPARATOR
Intervention: Diclofenac 0.1% ophthalmic solution
Number of subjects: 120
Study: 7653444

Group type: EXPERIMENTAL
Intervention: Fish oil (12 g/day of fish oil, approximately 8.5 g of n-3 fatty acids)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Rapeseed oil (12 g/day of rapeseed oil)
Number of subjects: 35
Study: 2765430

Group type: EXPERIMENTAL
Intervention: Mefenamic acid (500 mg thrice daily for 3‐5 days in two cycles)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Danazol (100 mg twice daily for 60 days)
Number of subjects: 40
Study: 837964

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 0
Study: 30851137

Group type: EXPERIMENTAL
Intervention: disposable device
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: eGO and mod devices
Number of subjects: 18

Group type: COMPARATOR
Intervention: all devices
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: mod, e-Pipe, and eGO
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: perceived speed of urge relief
Number of subjects: 18
Study: 26910818

Group type: EXPERIMENTAL
Intervention: Higher plasma tHcy concentrations in women
Number of subjects: 3309

Group type: EXPERIMENTAL
Intervention: Higher plasma tHcy concentrations in men
Number of subjects: 3309
Study: 25746563

Group type: EXPERIMENTAL
Intervention: Sumatriptan/Naproxen Sodium
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 34
Study: 24641096

Group type: EXPERIMENTAL
Intervention: Pulsed dye laser (PDL) treatment followed by twice daily applications of timolol gel
Number of subjects: 22

Group type: COMPARATOR
Intervention: Pulsed dye laser (PDL) treatment alone
Number of subjects: 22
Study: 22928795

Group type: EXPERIMENTAL
Intervention: Home care program (Choices for Healthy Aging [CHA])
Number of subjects: 298

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 298
Study: 19203157

Group type: EXPERIMENTAL
Intervention: ePREP intervention
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo intervention
Number of subjects: 77
Study: 17878954

Group type: EXPERIMENTAL
Intervention: Naturopathic care
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standardized physiotherapy
Number of subjects: 75
Study: 15083372

Group type: EXPERIMENTAL
Intervention: High-intensity pedaling exercise
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Medium-intensity pedaling exercise
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Low-intensity pedaling exercise
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: No-go P300 amplitude
Number of subjects: 12
Study: 11254820

Group type: EXPERIMENTAL
Intervention: Presence of malaria parasites in cord blood
Number of subjects: 658

Group type: EXPERIMENTAL
Intervention: Maternal asthma
Number of subjects: 658

Group type: EXPERIMENTAL
Intervention: Cord blood total IgE
Number of subjects: 658

Group type: EXPERIMENTAL
Intervention: Clinical episodes of malaria during infancy
Number of subjects: 658

Group type: EXPERIMENTAL
Intervention: Levels of indoor aeroallergens
Number of subjects: 658
Study: 9813535

Group type: EXPERIMENTAL
Intervention: Lightwand (Trachlight)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Direct-vision laryngoscopy (Macintosh laryngoscope)
Number of subjects: 40
Study: 7719523

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 78
Study: 2535870

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pyridoxine supplementation (10 mg per day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study: 30941799

Group type: EXPERIMENTAL
Intervention: Mother-peer-reared (MPR)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Nursery-reared (NR)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 97
Study: 28525825

Group type: EXPERIMENTAL
Intervention: Pre-pregnancy presence of similar symptoms
Number of subjects: 1482

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 1482

Group type: EXPERIMENTAL
Intervention: Recurrent UTI
Number of subjects: 1482

Group type: EXPERIMENTAL
Intervention: High hip circumference
Number of subjects: 1482

Group type: EXPERIMENTAL
Intervention: Vigorous exercising
Number of subjects: 1482

Group type: EXPERIMENTAL
Intervention: Induction of labor
Number of subjects: 1482

Group type: EXPERIMENTAL
Intervention: Forceps delivery
Number of subjects: 1482

Group type: EXPERIMENTAL
Intervention: 3rd degree perineal tear
Number of subjects: 1482

Group type: COMPARATOR
Intervention: Cesarean section
Number of subjects: 1482

Group type: EXPERIMENTAL
Intervention: Diagnosed depression (pre-pregnancy)
Number of subjects: 1482

Group type: EXPERIMENTAL
Intervention: High BMI (pre-pregnancy)
Number of subjects: 1482

Group type: EXPERIMENTAL
Intervention: Strenuous exercising (pre-pregnancy)
Number of subjects: 1482

Group type: EXPERIMENTAL
Intervention: Recurrent UTI (pre-pregnancy)
Number of subjects: 1482

Group type: EXPERIMENTAL
Intervention: Lower educational achievement (pre-pregnancy)
Number of subjects: 1482
Study: 26489389

Group type: EXPERIMENTAL
Intervention: Dexamethasone (two 4 mg tablets taken orally at least 1 hour before radiation treatment and daily for 4 days after)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Placebo (two placebo tablets taken orally at least 1 hour before radiation treatment and daily for 4 days after)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 298

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study: 23551928

Group type: EXPERIMENTAL
Intervention: Sexual health intervention
Number of subjects: 70
Study: 21555331

Group type: EXPERIMENTAL
Intervention: CRF(1) receptor antagonist R317573, 40 mg for 7 days
Number of subjects: 32

Group type: COMPARATOR
Intervention: Lorazepam (LZP), 2 mg as positive control on day 8
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 32
Study: 18423871

Group type: EXPERIMENTAL
Intervention: Early treated (ET)
Number of subjects: 401

Group type: COMPARATOR
Intervention: Conventional management (CM)
Number of subjects: 401
Study: 17061013

Group type: EXPERIMENTAL
Intervention: Computer-assisted training program plus the TSF manual
Number of subjects: 25

Group type: COMPARATOR
Intervention: Manual only
Number of subjects: 25
Study: 14501734

Group type: EXPERIMENTAL
Intervention: 0.4 mg tamsulosin once daily
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: 0.8 mg tamsulosin once daily
Number of subjects: 263

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 or 0.8 mg once daily) long-term
Number of subjects: 263
Study: 10936115

Group type: EXPERIMENTAL
Intervention: Metered-dose inhalers (MDIs) with Nebulizer Chronologs (NCs) monitoring
Number of subjects: 101

Group type: COMPARATOR
Intervention: Participants with full foreknowledge of the MDI monitoring capability of the NC
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: NC data for dumpers
Number of subjects: 101
Study: 9062840

Group type: EXPERIMENTAL
Intervention: Intensive behavioral lifestyle intervention (weight loss goals of 5 to 15 lb, 20 weekly group meetings)
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Intensive behavioral lifestyle intervention
Number of subjects: 535

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 535
Study: 7995674

Group type: EXPERIMENTAL
Intervention: The Experimental Behavioral and Attitudinal Modification Project
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 3400411

Group type: EXPERIMENTAL
Intervention: Lorazepam 4 mg oral fast dissolving drug formulation (FDDF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31451520

Group type: EXPERIMENTAL
Intervention: Autofluorescence imaging (AFI) during surveillance
Number of subjects: 15

Group type: COMPARATOR
Intervention: Clinical identification of high risk prior to endpoint in surveillance group
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Autofluorescence imaging (AFI) during surgery
Number of subjects: 15

Group type: COMPARATOR
Intervention: Clinical identification of high risk prior to endpoint in surgery group
Number of subjects: 15
Study: 29206996

Group type: EXPERIMENTAL
Intervention: Fluorouracil-based CRT with oxaliplatin
Number of subjects: 1179

Group type: COMPARATOR
Intervention: Fluorouracil-based CRT alone
Number of subjects: 1179

Group type: EXPERIMENTAL
Intervention: TRG 0 + 1 (poor regression)
Number of subjects: 1179

Group type: EXPERIMENTAL
Intervention: TRG 2 + 3 (intermediate regression)
Number of subjects: 1179

Group type: EXPERIMENTAL
Intervention: TRG 4 (complete regression)
Number of subjects: 1179

Group type: EXPERIMENTAL
Intervention: TRG 2 + 3 vs TRG 0 + 1
Number of subjects: 1179
Study: 26425703

Group type: EXPERIMENTAL
Intervention: Trastuzumab 6 mg/kg IV in 90 min (n = 46)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl, n = 8)
Number of subjects: 54
Study: 23419655

Group type: EXPERIMENTAL
Intervention: Closed-loop stimulation (CLS)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Accelerometer (XL)
Number of subjects: 74

Group type: COMPARATOR
Intervention: No rate sensor (DDD)
Number of subjects: 74
Study: 21144106

Group type: EXPERIMENTAL
Intervention: Konjac glucomannan (KGM) 4.5 g/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (maize starch)
Number of subjects: 0
Study: 19239860

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 0
Study: 16939022

Group type: EXPERIMENTAL
Intervention: Crest SpinBrush Pro Clean (power toothbrush)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Manual toothbrush (ADA reference)
Number of subjects: 50
Study: 14997962

Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 10849526

Group type: EXPERIMENTAL
Intervention: IFO+GM‐CSF
Number of subjects: 56

Group type: COMPARATOR
Intervention: CY+GM‐CSF
Number of subjects: 56
Study: 9085304

Group type: EXPERIMENTAL
Intervention: Kapanol (24-hourly)
Number of subjects: 24

Group type: COMPARATOR
Intervention: MS Contin (12-hourly)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Kapanol
Number of subjects: 24

Group type: COMPARATOR
Intervention: MS Contin
Number of subjects: 24
Study: 8210613

Group type: EXPERIMENTAL
Intervention: Nicotine chewing gum (4 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Carbon monoxide (320 p.p.m.)
Number of subjects: 9
Study: 3327353

Group type: EXPERIMENTAL
Intervention: High-dose acetylsalicylic acid (ASA)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Dihydroergotamine-heparin (DHEH)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Both ASA and DHEH
Number of subjects: 82
Study: 29739654

Group type: EXPERIMENTAL
Intervention: Didactic teaching
Number of subjects: 213

Group type: COMPARATOR
Intervention: Video-based social learning
Number of subjects: 213
Study: 27573564

Group type: COMPARATOR
Intervention: Sorafenib (400 mg bid)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin (SorCDDP: sorafenib 400 mg bid; cisplatin 65 mg/m2, day 1, every 4-6 weeks)
Number of subjects: 108
Study: 26082887

Group type: EXPERIMENTAL
Intervention: White matter volume reduction analysis using SPM8 plus DARTEL in CBS patients
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: White matter volume reduction analysis using SPM8 plus DARTEL in RS patients
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Comparison of CBS and RS VOIs
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (age-matched controls)
Number of subjects: 83
Study: 23043164

Group type: EXPERIMENTAL
Intervention: Insulin analogs with rHuPH20
Number of subjects: 14

Group type: COMPARATOR
Intervention: Insulin analogs without rHuPH20
Number of subjects: 14
Study: 20881606

Group type: EXPERIMENTAL
Intervention: felodipine-ER 5 mg/d
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: amlodipine 5 mg/d
Number of subjects: 63

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 63
Study: 17940902

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 15940143

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (LGG)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Mixture of 4 probiotic strains (MIX)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study: 12828690

Group type: EXPERIMENTAL
Intervention: Purpura-level treatment (0.5 J/cm2 greater than the purpura threshold)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Purpura-free treatment (1.0 J/cm2 less than the purpura threshold)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Purpura-level treatment
Number of subjects: 11

Group type: COMPARATOR
Intervention: Purpura-free treatment
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Both treatments (purpura and purpura-free)
Number of subjects: 11
Study: 8692505

Group type: EXPERIMENTAL
Intervention: Ampicillin-sulbactam
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 120
Study: 1804645

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nisoldipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6376016

Group type: EXPERIMENTAL
Intervention: Guar mini‐tablets (5 g t.i.d.)
Number of subjects: 79
Study: 29941062

Group type: EXPERIMENTAL
Intervention: Extended ACT
Number of subjects: 180

Group type: COMPARATOR
Intervention: Brief ACT
Number of subjects: 180

Group type: COMPARATOR
Intervention: EC
Number of subjects: 180
Study: 27543734

Group type: EXPERIMENTAL
Intervention: Squeezable bottle
Number of subjects: 80

Group type: COMPARATOR
Intervention: Syringe
Number of subjects: 80
Study: 25759001

Group type: EXPERIMENTAL
Intervention: Increased insurance payments (full insurance support for children under 5 years old)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bonus payments to hospital staff
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study: 25123988

Group type: EXPERIMENTAL
Intervention: Testosterone 2% solution applied after deodorant/antiperspirant to shaved axillae
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Testosterone 2% solution applied to unshaved axillae
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All treatments (including deodorant/antiperspirant and shaved/unshaved axillae)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 30
Study: 22044402

Group type: EXPERIMENTAL
Intervention: PF-04457845 (single dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PF-04457845 (multiple dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PF-04457845 (up to 40 mg single dose and 8 mg once daily for 14 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: PF-04457845
Number of subjects: 0
Study: 21039313

Group type: EXPERIMENTAL
Intervention: Allyl isothiocyanate (AITC)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Benzylisothiocyanate (BITC)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Phenylethylisothiocyanate (PEITC)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Sulforaphane (SFN)
Number of subjects: 85
Study: 17384828

Group type: COMPARATOR
Intervention: VVI pacing mode
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: DDD pacing mode
Number of subjects: 27
Study: 15867038

Group type: EXPERIMENTAL
Intervention: In-line blood gas and chemistry monitor
Number of subjects: 93
Study: 11952486

Group type: EXPERIMENTAL
Intervention: Fucidic acid (1.0%) eye drops applied twice per day
Number of subjects: 456

Group type: COMPARATOR
Intervention: Chloramphenicol (0.5%) eye drops applied six times per day
Number of subjects: 456
Study: 9708589

Group type: EXPERIMENTAL
Intervention: Risk information about complications from allogeneic blood transfusions
Number of subjects: 412

Group type: COMPARATOR
Intervention: Prior knowledge (uninformed group)
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Risk information
Number of subjects: 412
Study: 7624190

Group type: EXPERIMENTAL
Intervention: Occluded vision and visual imagery
Number of subjects: 80

Group type: COMPARATOR
Intervention: Visual imagery
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Occluded vision subjects
Number of subjects: 80
Study: 2374773

Group type: EXPERIMENTAL
Intervention: Bright light (2,500 lux) for 2 hours daily
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Dim light (50 lux) for 2 hours daily
Number of subjects: 42
Study: 115046

Group type: EXPERIMENTAL
Intervention: Decanoate of flupenthixol
Number of subjects: 51

Group type: COMPARATOR
Intervention: Decanoate of fluphenazine
Number of subjects: 51

Group type: COMPARATOR
Intervention: Both drugs (flupenthixol and fluphenazine)
Number of subjects: 51
Study: 31978436

Group type: EXPERIMENTAL
Intervention: Internal iliac artery balloon occlusion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard management (Control)
Number of subjects: 40
Study: 30950656

Group type: COMPARATOR
Intervention: Normal weight patients (BMI 18.5 kg/m2 ≤ BMI < 25 kg/m2)
Number of subjects: 2153

Group type: COMPARATOR
Intervention: Overweight patients (BMI 25 kg/m2 ≤ BMI < 30 kg/m2)
Number of subjects: 2153

Group type: EXPERIMENTAL
Intervention: Obese patients (BMI ≥30 kg/m2)
Number of subjects: 2153
Study: 28122207

Group type: EXPERIMENTAL
Intervention: Advergame promoting energy-dense snacks
Number of subjects: 597

Group type: COMPARATOR
Intervention: Advergame promoting nonfood products
Number of subjects: 597
Study: 25982025

Group type: EXPERIMENTAL
Intervention: MenPF-1 vaccine (25 μg or 50 μg doses)
Number of subjects: 52
Study: 23896353

Group type: EXPERIMENTAL
Intervention: Intravenous cortisol (100mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 22024004

Group type: EXPERIMENTAL
Intervention: Strongest Families intervention (treatment)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 243
Study: 19526040

Group type: EXPERIMENTAL
Intervention: Continuous therapy with GTN (0.6 mg/h 24 h/day for 7 days)
Number of subjects: 28

Group type: COMPARATOR
Intervention: No therapy (Control)
Number of subjects: 28
Study: 16904524

Group type: EXPERIMENTAL
Intervention: Clinical intervention including an information session, the use of a pain diary, and the possibility to contact a physician to adjust the pain medication
Number of subjects: 64

Group type: COMPARATOR
Intervention: Usual treatment of pain by the staff radiation oncologist
Number of subjects: 64
Study: 15265053

Group type: EXPERIMENTAL
Intervention: BIBN 4096 BS (0.1, 0.25, 0.5, 1, 2.5, 5, and 10 mg)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: BIBN 4096 BS (10 mg)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: BIBN 4096 BS (5 and 10 mg)
Number of subjects: 55
Study: 11590675

Group type: EXPERIMENTAL
Intervention: Direct stenting
Number of subjects: 197

Group type: COMPARATOR
Intervention: Secondary stenting
Number of subjects: 197
Study: 9119883

Group type: EXPERIMENTAL
Intervention: CM101 (7.5 micrograms/kg, 15 micrograms/kg, 24.75 micrograms/kg, 37.5 micrograms/kg) administered via i.v. infusion over 15 min, one cycle of therapy consisting of three treatments during 1 week.
Number of subjects: 15
Study: 8353062

Group type: EXPERIMENTAL
Intervention: text-plus-picture condition
Number of subjects: 59

Group type: COMPARATOR
Intervention: text-plus-text condition
Number of subjects: 59
Study: 2956983

Group type: EXPERIMENTAL
Intervention: Thymoxamine (0.15 mg kg‐1 loading dose followed by 0.15 mg kg‐1 h‐1)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine (1.5 mg loading dose followed by 1.5 mg h‐1)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 5
Study: 31608416

Group type: EXPERIMENTAL
Intervention: 6-month aerobic exercise programme (14 males, 11 females)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Balance and flexibility programme (15 males, 10 females)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 6-month aerobic exercise programme
Number of subjects: 50
Study: 29500209

Group type: EXPERIMENTAL
Intervention: 7-day treatment arm (7 days of cefuroxime/cefuroxime axetil followed by 3 days of blinded placebo)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: 10-day treatment arm (7 days of cefuroxime/cefuroxime axetil followed by 3 days of blinded cefuroxime axetil)
Number of subjects: 221
Study: 27506742

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (dietary management and increased physical activity)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 87
Study: 24885793

Group type: EXPERIMENTAL
Intervention: Fresh embryo transfer on day 3 after oocyte retrieval
Number of subjects: 1180

Group type: COMPARATOR
Intervention: Elective embryo cryopreservation followed by frozen-thawed embryo transfer
Number of subjects: 1180
Study: 22694906

Group type: EXPERIMENTAL
Intervention: adjunctive group interpersonal psychotherapy (IPT) for MDD
Number of subjects: 38

Group type: COMPARATOR
Intervention: attention‐matched control condition
Number of subjects: 38